UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATIONAsset Purchase Agreement • June 27th, 2024 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances)
On June 26, 2024, Coherus BioSciences, Inc., a Delaware corporation (“Coherus”), entered into an Asset Purchase Agreement (the “Purchase Agreement”) by and between Coherus and Hong Kong King-Friend Industrial Company Ltd., a Hong Kong corporation (“HKF”). HKF is the parent company of Meitheal Pharmaceuticals, Inc., a Delaware corporation.
ASSET PURCHASE AGREEMENT BY AND BETWEEN COHERUS BIOSCIENCES, INC. AND HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. DATED AS OF JUNE 26, 2024 Asset Purchase Agreement • June 27th, 2024 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • Delaware
This ASSET PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of June 26, 2024 by and among COHERUS BIOSCIENCES, INC., a Delaware corporation (“Seller”), and HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD., a Hong Kong corporation (“Buyer”). Each of Seller and Buyer are referred to herein as a “Party” and together as the “Parties.” Capitalized terms used but not otherwise defined herein have the meanings set forth in Article I.
